Bethan Balch
Bethan Balch has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Akish Luintel
Institute of Global Health Innovation, Imperial College London, UK
2 shared publications - Cecilia Vindrola-Padros
Rapid Research Evaluation and Appraisal Lab (RREAL), Department of Targeted Intervention, University College London, London, WC1E 6BT, UK
2 shared publications - Emma McGuire
Division of Infection, Barts Health NHS Trust, London, United Kingdom
2 shared publications - Gráinne Brady
Department of Targeted Intervention, University College London, London, UK
2 shared publications - Gwenan M. Knight
London School of Hygiene and Tropical Medicine
2 shared publications - Laura Shallcross
Institute of Health Informatics, University College London, London, UK
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e94014
Extent of Digital Health Fragmentation and Potential Implications for Antimicrobial Prescribing: Rapid Evidence Review
Background: Prior microbiology results, resistance patterns, and antimicrobial exposure are central to safe and effective antimicrobial prescribing. Digital health fragmentation refers to the dispersal of patient data across multiple electronic systems and the associated challenge of accessing complete information at the point of care. Antimicrobial prescribing for infections represents a critical use case to investigate the impact of digital health fragmentation on patient care. While interoperability has been studied in the context of patient safety, no review has described digital health fragmentation within the United Kingdom and examined its impact on antimicrobial prescribing and antimicrobial stewardship (AMS). Objective: This study aimed to (1) characterize the extent of digital health fragmentation in the United Kingdom, (2) summarize the available evidence on its impact on AMS and prescribing practices in high-income countries, and (3) identify potential solutions. Methods: A rapid review of the peer-reviewed literature was conducted following published guidance for rapid reviews and the PRISMA (Preferred Reporting Items of Systematic Reviews and Meta-Analyses) statement. MEDLINE ALL and PsycInfo were searched on August 19, 2025, using search terms relating to digital health fragmentation or interoperability, patient safety, and antimicrobial use. Searches were limited to English-language publications from 2015 (for characterizing the recent trends or current state of digital health fragmentation in the United Kingdom) or 2010 onward (for AMS-related impacts and solutions). Screening was conducted by 4 researchers following predefined inclusion and exclusion criteria. Extracted data were synthesized narratively through framework analysis. Study quality was appraised using the Mixed Methods Appraisal Tool. Results: Fourteen studies met the inclusion criteria. Ten studies described the extent and nature of digital health fragmentation in the United Kingdom. Digital health fragmentation affects a large number of patients and is linked to clinical care efficiency, quality, and safety risks, including limited access to external clinical records, missing or incomplete information, duplicate investigations, delays in decision‑making, and substantial time spent searching for data. Evidence specific to antimicrobial prescribing was limited (4 studies) but indicated that AMS relies on information spread across multiple systems, with poor interoperability disrupting workflows, hindering communication, and undermining stewardship activities. Only 1 study reported the development of a digital tool designed to address digital health fragmentation and support AMS. Conclusions: Digital health fragmentation negatively affects patient care across the United Kingdom, yet evidence on how it impacts AMS remains scarce. Given the urgency of the global antimicrobial resistance crisis, future research should therefore quantify the scale and impact of digital health fragmentation for AMS to inform investment and innovation in digital infrastructure and clinical-supportive solutions. Trial Registration: PROSPERO CRD420251126067; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251126067
- 6 October 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e94014
Open AccessExtent of Digital Health Fragmentation and Potential Implications for Antimicrobial Prescribing: Rapid Evidence Review
Background: Prior microbiology results, resistance patterns, and antimicrobial exposure are central to safe and effective antimicrobial prescribing. Digital health fragmentation refers to the dispersal of patient data across multiple electronic systems and the associated challenge of accessing complete information at the point of care. Antimicrobial prescribing for infections represents a critical use case to investigate the impact of digital health fragmentation on patient care. While interoperability has been studied in the context of patient safety, no review has described digital health fragmentation within the United Kingdom and examined its impact on antimicrobial prescribing and antimicrobial stewardship (AMS). Objective: This study aimed to (1) characterize the extent of digital health fragmentation in the United Kingdom, (2) summarize the available evidence on its impact on AMS and prescribing practices in high-income countries, and (3) identify potential solutions. Methods: A rapid review of the peer-reviewed literature was conducted following published guidance for rapid reviews and the PRISMA (Preferred Reporting Items of Systematic Reviews and Meta-Analyses) statement. MEDLINE ALL and PsycInfo were searched on August 19, 2025, using search terms relating to digital health fragmentation or interoperability, patient safety, and antimicrobial use. Searches were limited to English-language publications from 2015 (for characterizing the recent trends or current state of digital health fragmentation in the United Kingdom) or 2010 onward (for AMS-related impacts and solutions). Screening was conducted by 4 researchers following predefined inclusion and exclusion criteria. Extracted data were synthesized narratively through framework analysis. Study quality was appraised using the Mixed Methods Appraisal Tool. Results: Fourteen studies met the inclusion criteria. Ten studies described the extent and nature of digital health fragmentation in the United Kingdom. Digital health fragmentation affects a large number of patients and is linked to clinical care efficiency, quality, and safety risks, including limited access to external clinical records, missing or incomplete information, duplicate investigations, delays in decision‑making, and substantial time spent searching for data. Evidence specific to antimicrobial prescribing was limited (4 studies) but indicated that AMS relies on information spread across multiple systems, with poor interoperability disrupting workflows, hindering communication, and undermining stewardship activities. Only 1 study reported the development of a digital tool designed to address digital health fragmentation and support AMS. Conclusions: Digital health fragmentation negatively affects patient care across the United Kingdom, yet evidence on how it impacts AMS remains scarce. Given the urgency of the global antimicrobial resistance crisis, future research should therefore quantify the scale and impact of digital health fragmentation for AMS to inform investment and innovation in digital infrastructure and clinical-supportive solutions. Trial Registration: PROSPERO CRD420251126067; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251126067
- Open Access
- 23 February 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Digital health fragmentation and patient safety outcomes with respect to antimicrobial prescribing: A rapid evidence review (Preprint)
BACKGROUND Prior microbiology results, resistance patterns, and antimicrobial exposure are central to safe and effective antimicrobial prescribing. Digital health fragmentation refers to the dispersal of patient data across multiple electronic systems and the associated challenge of accessing complete information at the point of care. Antimicrobial prescribing for infections represents a critical use case to investigate the impact of digital health fragmentation on patient care. While interoperability has been studied in the context of patient safety, no review has described digital health fragmentation within the UK and examined its impact on antimicrobial prescribing and antimicrobial stewardship (AMS). OBJECTIVE To (1) characterise the extent of digital health fragmentation in the UK, (2) summarise the available evidence on its impact on AMS and prescribing practices, and (3) identify potential solutions. METHODS A rapid review of the peer-reviewed literature was conducted following published guidance for rapid reviews and the PRISMA statement. MEDLINE ALL and PsycInfo were searched on 19 August 2025 using search terms relating to digital health fragmentation/interoperability, patient safety, and antimicrobial use. Searches were limited to English-language publications from 2015 (for characterising the recent trends/current state of digital health fragmentation in the UK) or 2010 onwards (for AMS-related impacts and solutions). Screening was conducted by four researchers following pre-defined inclusion and exclusion criteria. Extracted data were synthesised narratively through framework analysis. Study quality was appraised using the Mixed Methods Appraisal Tool. RESULTS Fourteen studies met the inclusion criteria. Ten studies described the extent and nature of digital health fragmentation in the UK. Digital health fragmentation affects a large number of patients and is linked to clinical care efficiency, quality and safety risks, including limited access to external clinical records, missing or incomplete information, duplicate investigations, delays in decision‑making, and substantial time spent searching for data. Evidence specific to antimicrobial prescribing was limited (four studies) but indicated that AMS relies on information spread across multiple systems, with poor interoperability disrupting workflows, hindering communication, and undermining stewardship activities. Only one study reported the development of a digital tool designed to address digital health fragmentation and support stewardship. CONCLUSIONS Digital health fragmentation negatively affects patient care across the UK, yet evidence on which specific aspects of fragmentation most undermine antimicrobial stewardship remains scarce. AMS represents a critical use case to understand how and why digital health fragmentation has detrimental impacts on patient safety and the need for investment and innovation. Given the urgency of the global antimicrobial resistance crisis, future research should therefore quantify the scale and impact of fragmentation for AMS to direct investment and innovation in digital infrastructure and clinical-supportive solutions. CLINICALTRIAL PROSPERO (CRD420251126067)
- 23 February 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDigital health fragmentation and patient safety outcomes with respect to antimicrobial prescribing: A rapid evidence review (Preprint)
BACKGROUND Prior microbiology results, resistance patterns, and antimicrobial exposure are central to safe and effective antimicrobial prescribing. Digital health fragmentation refers to the dispersal of patient data across multiple electronic systems and the associated challenge of accessing complete information at the point of care. Antimicrobial prescribing for infections represents a critical use case to investigate the impact of digital health fragmentation on patient care. While interoperability has been studied in the context of patient safety, no review has described digital health fragmentation within the UK and examined its impact on antimicrobial prescribing and antimicrobial stewardship (AMS). OBJECTIVE To (1) characterise the extent of digital health fragmentation in the UK, (2) summarise the available evidence on its impact on AMS and prescribing practices, and (3) identify potential solutions. METHODS A rapid review of the peer-reviewed literature was conducted following published guidance for rapid reviews and the PRISMA statement. MEDLINE ALL and PsycInfo were searched on 19 August 2025 using search terms relating to digital health fragmentation/interoperability, patient safety, and antimicrobial use. Searches were limited to English-language publications from 2015 (for characterising the recent trends/current state of digital health fragmentation in the UK) or 2010 onwards (for AMS-related impacts and solutions). Screening was conducted by four researchers following pre-defined inclusion and exclusion criteria. Extracted data were synthesised narratively through framework analysis. Study quality was appraised using the Mixed Methods Appraisal Tool. RESULTS Fourteen studies met the inclusion criteria. Ten studies described the extent and nature of digital health fragmentation in the UK. Digital health fragmentation affects a large number of patients and is linked to clinical care efficiency, quality and safety risks, including limited access to external clinical records, missing or incomplete information, duplicate investigations, delays in decision‑making, and substantial time spent searching for data. Evidence specific to antimicrobial prescribing was limited (four studies) but indicated that AMS relies on information spread across multiple systems, with poor interoperability disrupting workflows, hindering communication, and undermining stewardship activities. Only one study reported the development of a digital tool designed to address digital health fragmentation and support stewardship. CONCLUSIONS Digital health fragmentation negatively affects patient care across the UK, yet evidence on which specific aspects of fragmentation most undermine antimicrobial stewardship remains scarce. AMS represents a critical use case to understand how and why digital health fragmentation has detrimental impacts on patient safety and the need for investment and innovation. Given the urgency of the global antimicrobial resistance crisis, future research should therefore quantify the scale and impact of fragmentation for AMS to direct investment and innovation in digital infrastructure and clinical-supportive solutions. CLINICALTRIAL PROSPERO (CRD420251126067)